TABLE 14.
Uncompetitive Antagonist | GluA1 | GluA2 | GluA3 | GluA4 | GluA1/GluA2 |
---|---|---|---|---|---|
μM | |||||
Argiotoxin 636 | 0.35–3.4a,b | N.E.a | 0.23a | 0.43a | 300b |
Joro spider toxin | 0.04c | N.E.c | 0.03c | N.E.c | |
Philanthotoxin 433d | 0.8 | N.E. | |||
Philanthotoxin 343 | 2.8b | 270b | |||
Philanthotoxin 56 | 3.3 pMe | 5.2e | |||
Philanthotoxin 74 | 0.17e | 1.6e | |||
IEM-1460 | 1.6f | N.E.g | 1.6f | ||
IEM-1754 | 6.0f | 6.0f | |||
HPP-spermined | 0.5 | 0.08 | 0.5 | N.E. |
HPP-spermine, N-(4-hydroxyphenylpropanoyl)spermine trihydrochloride; IEM-1754, 1-ammonio-5-(1-adamantane-methylammoniopentane dibromide); N.E., no effect.
Herlitze et al. (1993); holding membrane potential was −70 mV.
Brackley et al. (1993); holding membrane potential, −80 mV.
Blaschke et al. (1993); holding membrane potential, −100 mV.
Washburn and Dingledine (1996); holding membrane potential, −70 mV. Although IC50 values were not calculated, initial experiments suggested that philanthotoxin-433 had a lower affinity for GluA1 and GluA4 receptors compared with GluA3.
Philanthotoxin 56 has an IC50 of 3.3 pM for recombinant GluA1 (Kromann et al., 2002); holding membrane potential, −80 mV.
Magazanik et al. (1997); holding membrane potential, −80 mV.
Schlesinger et al. (2005); holding membrane potential, −60 mV, recombinant human GluA2(R).